Global Cell Therapy Market

Cell Therapy Market Size, Share, Growth Analysis, By Therapy Type(Allogeneic Therapies (Stem Cell Therapies (Hematopoietic Stem Cell Therapies, Mesenchymal Stem Cell Therapies), Non-Stem Cell Therapies (Keratinocytes & Fibroblast-based Therapies, Others)), By Cell Type(Stem Cell (Bone Marrow, Blood, Umbilical Cord-Derived, Adipose-Derived Stem Cell), By Therapeutic Area(Oncology, Cardiovascular Disease (CVD), Musculoskeletal Disorders, Dermatology), By End User(Hospitals & Clinics, Academic & Research Institutes, and Others), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35H2061 | Region: Global | Published Date: June, 2024
Pages: 157 | Tables: 132 | Figures: 77

Cell Therapy Market Insights

Cell Therapy Market size was valued at USD 18.92 billion in 2019 and is poised to grow from USD 21.6 billion in 2023 to USD 71.07 billion by 2031, growing at a CAGR of 14.15% in the forecast period (2024-2031).

The growing number of clinical trials for cell-based treatments is driving the cell therapy industry. As a result, there has been a significant increase in worldwide investment in research and clinical translation. The presence of government and commercial funding bodies that are continuously giving funds to assist projects at various phases of clinical trials can be linked to the growing number of ongoing clinical studies.

In addition, advances in the field of regenerative medicine are likely to lead to more effective treatment options for chronic illnesses. Several businesses in U.S. and Canada are at the vanguard, attempting to profit from the market for cell therapy's untapped potential.

US Cell Therapy Market  is poised to grow at a sustainable CAGR for the next forecast year.

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Cell Therapy Market size was valued at USD 18.92 billion in 2019 and is poised to grow from USD 21.6 billion in 2023 to USD 71.07 billion by 2031, growing at a CAGR of 14.15% in the forecast period (2024-2031).

Companies are getting FDA permission for stem cell treatment for a variety of disorders and infections. For example, in September 2020, the FDA granted Stemedica Cell Technologies, Inc. Investigational New Drug permission to undertake phase II studies of intravenously delivered allogeneic MSCs in covid-19 patients. Ischemic-tolerant MSCs have various characteristics that make them an appealing potential biological treatment for COVID-19, including immunomodulatory effects, limited immunogenicity, and the ability to inhibit excessive pro-inflammatory responses. 'Novartis AG', 'Kite Pharma Inc. (a subsidiary of Gilead Sciences Inc.)', 'Vericel Corporation', 'Takeda Pharmaceutical Company Limited', 'Bluebird Bio Inc.', 'Celgene Corporation (now part of Bristol Myers Squibb)', 'Fate Therapeutics Inc.', 'Spark Therapeutics Inc. (a subsidiary of Roche Holding AG)', 'Osiris Therapeutics Inc. (a subsidiary of Smith & Nephew plc)', 'Fibrocell Science Inc. (now part of Castle Creek Pharmaceuticals LLC)', 'Mesoblast Limited', 'TiGenix NV (a subsidiary of Takeda Pharmaceutical Company Limited)', 'Sangamo Therapeutics Inc.', 'Celyad Oncology SA', 'Gamida Cell Ltd.', 'JCR Pharmaceuticals Co. Ltd.', 'Cytori Therapeutics Inc.', 'Athersys Inc.', 'DiscGenics Inc.', 'BrainStorm Cell Therapeutics Inc.'

The demand for novel, better medicines for illnesses like cancer and CVD has led to a rise in general research efforts, as well as financing for cell-based research. 

The expansion of the cell therapy market was aided by the growing frequency of chronic illnesses. Chronic illness is defined as a condition that lasts one year or more and requires medical treatment, affects everyday activities, or both, according to the US Centers for Disease Control and Prevention (CDC). It includes heart disease, cancer, diabetes, and Parkinson's disease. Patients with spinal cord injuries, type 1 diabetes, Parkinson's disease (PD), heart disease, cancer, and osteoarthritis may benefit from stem cells.

In 2020, North America is expected to have the biggest market share of 42.0%. The existence of a significant number of institutions and institutes involved in stem cell treatment research and development accounts for the region's large share. Five of the eight top colleges in the world are situated in the United States, including Stanford University's Institute for Stem Cell Biology and Regenerative Medicine, Harvard University's Harvard Stem Cell Institute, and Yale University's Yale Stem Cell Center. Over the projected period, the market for cell therapy in the Asia Pacific is expected to develop at a profitable rate. The growing investment by developers and customers in self-education for sophisticated medical therapies is expected to enhance the income generated by the region's expanding economies. In Asian nations, there are a number of stem cell consortiums whose goal is to ensure that R&D activities are well-coordinated and targeted. Furthermore, because of the legal framework's flexibility, patients from Western nations have been spotted migrating to Asian countries for treatment.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.


Feedback From Our Clients

Global Cell Therapy Market

Product ID: SQMIG35H2061